De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis

doi:10.3748/wjg.v19.i37.6278

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 37

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6167)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

478

HTML

3349

Figures (1-2)

224

Tables (1-2)

188

Sum=4239

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1026

Download

902

Sum=1928

Oct 7, 2013 (publication date) through Nov 18, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Oct 7, 2013; 19(37): 6278-6283
Published online Oct 7, 2013. doi: 10.3748/wjg.v19.i37.6278

Open in New Tab Full Size Figure Download Figure

Figure 1 Flow chart of patient conditions following treatment with de novo lamivudine and adefovir dipivoxil combination therapy and entecavir monotherapy for 96 wk. LAM: Lamivudine; ADV: Adefovir dipivoxil; ETV: Entecavir.

Open in New Tab Full Size Figure Download Figure

Figure 2 Kaplan-Meier analysis of cumulative survival rate in patients with hepatitis B virus-related decompensated cirrhosis treated with lamivudine and adefovir dipivoxil combination therapy and entecavir monotherapy for 96 wk. LAM: Lamivudine; ADV: Adefovir dipivoxil; ETV: Entecavir.

Citation: Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19(37): 6278-6283
URL: https://www.wjgnet.com/1007-9327/full/v19/i37/6278.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i37.6278